Eventide Asset Management COLL Position
Active3-Fund ConvergenceEventide Asset Management trimmed their position in COLLEGIUM PHARMACEUTICAL, INC (COLL) in Q4 2025, holding $86.9M worth of shares across 1,876,239 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
COLL is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 16.1% of float with 9.9 days to cover, indicating significant bearish positioning against Eventide's long thesis.
About COLLEGIUM PHARMACEUTICAL, INC
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Full company profile →Short Interest
16.1%
9.9 days to cover
Eventide Asset Management COLL Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 1,876,239 | -514,673 | $86.9M |
| Q3 2025 | Decreased | 2,390,912 | -250,489 | $83.7M |
| Q2 2025 | Increased | 2,641,401 | +1,854 | $78.1M |
| Q1 2025 | Increased | 2,639,547 | +845 | $78.8M |
| Q4 2024 | Increased | 2,638,702 | +3,296 | $75.6M |
| Q3 2024 | Increased | 2,635,406 | +750 | $101.8M |
| Q2 2024 | Increased | 2,634,656 | +615 | $84.8M |
| Q1 2024 | Increased | 2,634,041 | +3,563 | $102.3M |
| Q4 2023 | Decreased | 2,630,478 | -856 | $81.0M |
| Q3 2023 | Increased | 2,631,334 | +77 | $58.8M |
| Q2 2023 | Increased | 2,631,257 | +1,120 | $56.5M |
| Q1 2023 | New | 2,630,137 | +2,630,137 | $63.1M |
Frequently Asked Questions
Does Eventide Asset Management own COLL?
Yes. As of Q4 2025, Eventide Asset Management holds 1,876,239 shares of COLLEGIUM PHARMACEUTICAL, INC (COLL) valued at $86.9M. This data comes from their SEC 13F filing.
How many hedge funds own COLL?
3 specialist biotech hedge funds currently hold COLL, including Rock Springs Capital, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy COLL?
Eventide Asset Management's position in COLL was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's COLL position increasing or decreasing?
Eventide Asset Management trimmed their COLL position in the most recent quarter, reducing by 514,673 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
COLLCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →